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made using an existing code of practice for non-FFF beams, 
NCS-18 [1]. Therefore kQ values were obtained provided by 
the code of practice. The differences of the NCS-18 kQ values 
between FFF and FF beams were compared with the 
measured differences. 
 
 
 
Results: The average kQ of the six NCS-18 recommended 
chambers (i.e. the not waterproof types) are presented in 
the Table. Comparison between FFF and FF beams of the 
same nominal energy and pdd(10) show negligible differences 
of -0.001 (8) and 0.000 (9) for 6 and 10 MV respectively. 
Based on NCS-18, using quality index TPR20,10 the differences 
in kQ also show negligible deviations of respectively -0.002 (8) 
and -0.003 (9). The uncertainties, represented as the last 
significant digit between brackets, are reported with a 
coverage factor, k = 2. 
 
 
Conclusions: The differences between FFF and FF clinical 
photon beams of 6 and 10 MV for measured kQ values of six 
reference type ionization chambers with the same value for 
the beam quality index pdd(10) are negligible (< 0.001). 
Application of a TPR20,10 based protocol results in slightly 
higher differences (< 0.003). All differences are within the 
reported uncertainties. 
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Purpose/Objective: The combined simultaneous use of MRI 
and MV photon irradiations is one of the most promising 
innovations of cancer radiotherapy as it offers the capability 
of using non-ionizing radiation for high quality imaging with 
tissue selectivity to drive the delivery of therapeutic doses of 
ionizing radiation to tumour volumes. Clinical application of 
such facilities presents new dosimetric and radiobiological 
challenges. 
The aim of this work was to use 4 different chamber types 
and alanine dosimeters to determine correction factors and 
optimum set up for ionization chamber based dosimetry in an 
MR-linac. 
Materials and Methods: Measurements were made in the 
UMC Utrecht MR-linac facility (Elekta). Absorbed dose was 
measured at the isocentre in a static vertical beam, with the 
detector axis perpendicular to both the beam and magnetic 
field. A 10 cm x 10 cm field was set at the isocentre and 
measurements were made at 5cm depth in a water-
equivalent full scatter phantom. The chambers used were a 
PTW Farmer-type chamber (TW30012-1), a PTW waterproof 
Farmer-type chamber (TW30013), a 2611-type chamber and 
an Exradin A1SL chamber. Alanine pellets were used in a 
Farmer-shaped PEEK holder. 
Measurements were made in the conventional way to 
determine the corrections required for the effects due to 
both polarity and ion recombination. To investigate machine 
linearity, 500 – 5000MU were delivered to alanine pellets. 
Results: The alanine dosimeters used in the UMC-Utrecht MR-
linac were used to calibrate the MR-linac output. This was 
determined in terms of cGy / MU, using machine monitor 
units as the reference, as well as in terms of cGy / monitor 
chamber nC. The machine calibration was used to determine 
the dose delivered to each ionization chamber. For the same 
beams, each chamber also measured the total dose 
delivered. These results are shown in table 1. 
 
Table 1. The dose as measured by each of four ionisation 
chambers compared to the dose determined via calibration of 
the MR-linac output using alanine. 
Conclusions: The two Farmer chamber calibrations deviate 
from the alanine based calibration by 1.9% and measure a 
greater dose than the alanine. The 2611 chamber differs from 
the alanine measurement by 0.3% and measures a smaller 
dose than the alanine. The A1SL chamber differs by 2% from 
the alanine, measuring a smaller dose for the same 
conditions. 
The effect of a 1.5 T field on the polarity and ion 
recombination corrections was expected to be small (Smit et 
al. 2013) and the results of this work agree with this for all 
chamber types. Within uncertainty, the dose response of 
alanine and the 2611 monitor ionization chamber was linear 
with delivered monitor units. 
The correction for the effect of the magnetic field will be 
determined by measurements on a theratron cobalt-60 
facility which has just had a 1.5T magnet installed. 
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Purpose/Objective: Relevant dosimetric errors, which can be 
identified using sub-arc analyses, may be obscured when 
performing integral dose QA for VMAT. Sub-arc EPID-based 
pre-treatment dose verification requires synchronization of 
the acquired images to Control Points (CPs). Published 
methods use logging features provided by the linac vendor or 
specific hardware solutions. This work aimed to develop an 
independent software-based synchronization method relying 
exclusively on information from the acquired images. 
Moreover, the sensitivity of this novel QA method to detect 
clinically relevant errors in leaf positioning and dose rate was 
assessed, both for sub-arc and integral dose QA. 
Materials and Methods: During VMAT delivery, raw EPID 
images are continuously acquired. The images are converted 
to Portal Dose Images (PDI) after correction for EPID induced 
effects like crosstalk. In contrast to other methods, 
synchronization of images to CPs of the VMAT sequence is 
based on the near maximum grey value in each image. The 
ratio between this value and the sum of all near maxima is 
proportional to the number of MU delivered during 
acquisition of that image. From the CPs, both the integral 
VMAT fluence and fluences corresponding to 10 ME sub-arcs 
can be derived, taking into account the dynamic behaviour of 
the plan. The method was tested using a cooled CCD-camera 
based EPID at six Elekta linacs for a group of 15 prostate 
cancer patients. PDI predictions were compared to the 
measurements using a gamma evaluation with 2%/2mm 
reference values for integral dose QA and 3%/3mm for sub-
arc analyses. To assess the methods sensitivity, systematic 
and temporal perturbations in MLC positioning and dose 
delivery were introduced in a nominal plan. 
Results: For the 15 patients, on average 99.6 ± 0.3% (1 SD) of 
pixels passed the gamma test for integral VMAT QA. The 
average mean gamma was 0.30 ± 0.02. Also sub-arc analyses 
showed good results with overall mean pass rates of 98.6 ± 
0.9% and median mean gamma values of 0.25 ± 0.02 (see 
Figure 1). In time and between different linacs the QA results 
were highly reproducible. By evaluating integral PDIs, errors 
in MLC leaf positioning, reducing the distance between 
opposing leaves by 1 mm, resulting in a 2.4% change in mean 
prostate dose, could easily be detected. Using sub-arc 
analyses, temporal perturbations, like a stuck leaf for 5 CPs 
resulted in a large increase in near maximum gamma values 
(γ1). Temporal dose perturbations, like an addition or 
reduction of 1 MU per CP over a range of 10 CPs, while 
maintaining the overall number of MUs constant, were also 
clearly detectable. 
Conclusions: A novel method to synchronize acquired EPID 
images to VMAT delivery was developed, allowing accurate 
sub-arc VMAT dose verification. Without major adaptations it 
can also be used in other clinics. Even small deviations to 
nominal treatment plans could easily be detected. Currently, 
we apply this method routinely for VMAT QA. 
 
 
   
OC-0555   
Development of action levels for patient error detection 
for an EPID based real-time delivery verification system 
T. Fuangrod1, H. Woodruff2, P.B. Greer3, R. Middleton1 
1University of Newcastle, School of Electrical Engineering 
and Computer Science, Newcastle NSW, Australia  
2University of Newcastle, School of Mathematical and 
Physical Sciences, Newcastle NSW, Australia  
3Calvary Mater Newcastle, Radiation Oncology, Newcastle 
NSW, Australia  
 
Purpose/Objective: The purpose of this study is to develop 
statistically based action levels for error detection during 
real-time EPID-based patient treatment verification for IMRT 
and VMAT based on measured real-time patient verification 
results. 
Materials and Methods: The real-time verification system 
(Watchdog) utilises a comprehensive physics-based model to 
generate a series of predicted transit cine EPID image as a 
reference data set, and compares these to measured cine-
EPID images acquired during treatment. The agreement 
between the predicted and measured transit images is 
quantified using chi-comparison (currently 4%,4 mm) on a 
cumulative frame basis.  
Cine-EPID images were acquired from the first two fractions 
of 37 IMRT patients to generate the action levels; 10 Prostate 
treatments, 10 head and neck treatments, 7 Pelvic 
treatments, and 10 rectum treatments. Statistical process 
control (SPC) was used to generate the action levels at 3 
standard deviations from the mean for each treatment site. 
The action level function is separated into two phases; 0-2 
seconds, and >2 seconds to account for uncertainty at the 
beginning of image acquisition.  
Results: In the first 2 seconds of treatment, a linear action 
function was defined (see figure). The derived action levels 
(4%,4 mm) after 2 seconds of image acquisition for prostate, 
H&N, pelvic, and rectum were 67%, 50%, 63%, and 61% 
respectively. In the figure, an error detected toward the end 
of the treatment course for a head and neck patient 
correlated with weight loss shown on CBCT scans. 
 
Conclusions: We have developed preliminary action levels for 
a real-time EPID based treatment verification system 
(Watchdog). These action levels are designed to be applied to 
real-time verification during treatment with immediate 
intervention during SBRT treatments and post-delivery 
investigation during standard fractionation. Initial results 
found that the system detected significant changes in patient 
contour due to weight loss for a head and neck treatment.  
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